The study, published in a peer-reviewed American Cancer Society journal, found that the benefit becomes pronounced within two years of therapy and is maintained throughout its use.
Tamoxifen has been shown to reduce the risk of breast cancer recurrence by as much as 50%. In addition, increasing evidence indirectly supports its protective effects on the heart. Studies have shown women taking tamoxifen show reductions in markers of cardiac disease, such as bad cholesterol and homocysteine. However, there is little direct evidence of tamoxifen’s heart protective benefits by way of reduced morbidity or mortality.
To evaluate its hypothesized cardioprotective affects, a team of investigators from Boston University’s Schools of Medicine and Public Health reviewed the records of 3,030 breast cancer patients treated with tamoxifen and 4,233 patients with other cancers not treated with tamoxifen.
Women treated with tamoxifen were less likely to develop symptomatic heart disease than those who did not receive tamoxifen. On further analysis, current use of tamoxifen was associated with significantly reduced risk of heart disease. Moreover, the reduced heart disease effects were observed in women who had completed less than two years of therapy and continued throughout the duration of the five years of recommended therapy.
Tamoxifen is marketed as Nolvadex by AstraZeneca, as Soltamox by Savient Pharmaceuticals subsidiary Rosemont Pharmaceuticals, and as Tamofen by Pharmacia & Upjohn.